# A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)

> **NCT05094336** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Amgen** · enrollment: 329 (actual)

## Conditions studied

- Advanced MTAP-null Solid Tumors

## Interventions

- **DRUG:** Anvumetostat
- **DRUG:** Docetaxel
- **DRUG:** Comparator Anvumetostat Test Tablet

## Key facts

- **NCT ID:** NCT05094336
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-01
- **Primary completion:** 2026-05-27
- **Final completion:** 2028-05-29
- **Target enrollment:** 329 (ACTUAL)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05094336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05094336, "A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05094336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*